NEW YORK (GenomeWeb News) — EuroGentest is expected to announce next week that it is evaluating a pyrophosphorolysis activated polymerization assay for prenatal screening through Europe’s Special Non-invasive Advances in Fetal and NeoNatal Evaluation Network (SAFE) and another of its Excellence programs.
 
The PAP assay, a non-invasive prenatal screening test, uses maternal plasma to detect rare mutations and to determine fetal sex.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.